(MedPage Today) — Two insulin-dependent adolescents with type 1 diabetes and obesity had metabolic improvements after starting a low-dose GLP-1 agent, a case series showed.
One year after adding injectable semaglutide (Ozempic, Wegovy) to lifestyle…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
